Tempus AI
This study is a non-interventional, multicenter, multicohort evaluation of participants with cancer who will undergo longitudinal plasma ctDNA biomarker profiling at specific time points in addition to standard of care therapy.
Cancer
| Study Type : | Observational |
| Estimated Enrollment : | 500 participants |
| Official Title : | TEMPUS ARIES: A Biobank Registry Platform Study in Oncology |
| Actual Study Start Date : | June 1, 2024 |
| Estimated Primary Completion Date : | June 1, 2029 |
| Estimated Study Completion Date : | June 1, 2029 |
Information not available for Arms and Intervention/treatment
| Ages Eligible for Study: | 18 Years to 99 Years |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.